Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
April 30, 2007
- Korosho Group Discusses Direct Contracts between Sponsors and Investigators
April 30, 2007
- Symposium
April 30, 2007
- R&D NEWS IN BRIEF
April 30, 2007
- India Featured at CPhi 2007
April 30, 2007
- Roche to Acquire BioVeris
April 30, 2007
- SymBio to Develop Bendamustine in Asia-Pacific Rim Countries
April 30, 2007
- MEDICAL DEVICE NEWS IN BRIEF
April 30, 2007
- Molecular Imaging Using PET Increases Efficiency of Drug Development
April 23, 2007
- Personalized Medicine Is within Our Reach: Prof. Nakamura
April 23, 2007
- R&D NEWS IN BRIEF
April 23, 2007
- Korosho Recommends Measures against MDRP
April 23, 2007
- REGULATORY NEWS IN BRIEF
April 23, 2007
- MEDICAL DEVICE NEWS IN BRIEF
April 23, 2007
- Crestor Effective in Low-Risk Arteriosclerosis Patients: METEOR Study
April 23, 2007
- Sawai to Increase Calls to DPC Hospitals
April 23, 2007
- NEW PRODUCT／Follistim Launched for New Indication: Nippon Organon
April 23, 2007
- GENERIC NEWS IN BRIEF
April 23, 2007
- Shionogi to Hire More MRs to Promote Crestor, Irbesartan
April 23, 2007
- Medical Spending Should Be Increased: JMA President
April 23, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…